Lusaris Launches with $60M to Advance Psychedelic-Based Depression Therapeutic

Lusaris Therapeutics launched Wednesday with a $60 million Series A financing round with the goal of advancing LSR-1019, a sublingual formulation of 5-MeO-DMT in development for treatment-resistant depression (TRD).